TIFFANY TABIAI: Open Payments
NPI 1477162204 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$406 in 21 payments from 12 companies in 2025. Trend: 2023 $129 · 2024 $216 · 2025 $406
Food & beverage: $406
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $94 |
| PFIZER INC. | 4 | $73 |
| Novo Nordisk Inc | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $35 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| Dexcom, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
Products named: PREVNAR 20, UBRELVY, QULIPTA, CAPLYTA, TRELEGY ELLIPTA, Wegovy, Dexcom G6 Transmitter, Veozah.
Industry payments across OK — which companies pay providers there.
